IDROWIN Tablets

IDROWIN tablets contain Ibandronic Acid 150mg, formulated as an oral dosage intended for the management of postmenopausal osteoporosis in patients with increased fracture risk. Ibandronic acid acts at the bone tissue level by inhibiting osteoclast-mediated bone resorption, thereby helping to slow the rate of bone loss and support maintenance of bone mineral density. Through its action on bone remodeling pathways, the drug contributes to structural bone integrity over time.

Each tablet of IDROWIN is manufactured to ensure consistent strength and bioavailability. Packaging and stability controls are implemented to preserve tablet integrity and dosing reliability for patients and healthcare providers.

⚠️ Precautions: Take IDROWIN exactly as instructed by a healthcare professional. For oral tablets, swallow whole with a full glass of plain water on an empty stomach and remain upright for at least 30 minutes (do not lie down) to reduce the risk of esophageal irritation; do not chew or crush. Confirm normal calcium levels prior to initiation; avoid in known hypocalcemia. Use caution in patients with severe renal impairment and contraindicated in pregnancy and breastfeeding unless advised. Report any difficulty swallowing, severe heartburn, or new thigh/hip pain. Inform the prescriber of concomitant medications and medical history.